RESUMO
Feibi decoction (FBD) is a traditional Chinese herbal medicine and has been clinically used in the treatment of pulmonary fibrosis (PF), which is characterized by diffuse interstitial inflammation and exaggerated collagen accumulation. However, the potential mechanisms remain to be elucidated. The present study aimed to investigate the effect of FBD-medicated serum (FBDS) on lipopolysaccharide (LPS)-induced inflammation in macrophages. In RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs), FBDS treatment significantly inhibited the production of pro-inflammatory cytokines induced by LPS. In addition, it was indicated that FBDS treatment suppressed the activation of NF-κB and Smad2/Smad3 following LPS treatment. Furthermore, FBDS treatment decreased the expression of transforming growth factor-ß1 and chitinase-3-like protein 1. In conclusion, the results demonstrated that treatment with FBDS inhibited LPS-induced inflammation in RAW264.7 and BMDM cells. These data may improve understanding of the effect of FBD on anti-inflammation and help determine the mechanisms underlying the alleviation of PF via FBD.
RESUMO
Objective To study the effect and mechanism of Feibi Decoction on pulmonary fibrosis.Methods SD rats were randomly divided into sham-operation group,model control group,Feibi Decoction large-close group,Feibi Decoction mid-dose group,Feibi Decoction samll-dose group and western medicine control group,each of 10 rats.Bleomycetin was used to copy rat's pulmonary fibrosis model.Feibi decoction was drenched to rats in large,medium and small dose of Chinese medicine groups.Prednisone was given to werstern medicine control group.The rats were executed 28 days later.The expression of p38 MAPK and transforming growth factor ?1(TGF-?1) was tested.Results In comparison with sham operation,Chinese medicine and western medicine groups,the expression of p38 MAPK and TGF-?1 in model control group increased significantly(P